These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 7865168)
1. Effect of dizocilpine (MK-801) on the catalepsy induced by delta 9-tetrahydrocannabinol in mice. Kinoshita H; Hasegawa T; Katsumata Y; Kameyama T; Yamamoto I; Nabeshima T J Neural Transm Gen Sect; 1994; 95(2):137-43. PubMed ID: 7865168 [TBL] [Abstract][Full Text] [Related]
2. Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice. Kinoshita H; Hasegawa T; Kameyama T; Yamamoto I; Nabeshima T Neurosci Lett; 1994 Jun; 174(1):101-4. PubMed ID: 7970141 [TBL] [Abstract][Full Text] [Related]
3. Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. Sano K; Mishima K; Koushi E; Orito K; Egashira N; Irie K; Takasaki K; Katsurabayashi S; Iwasaki K; Uchida N; Egawa T; Kitamura Y; Nishimura R; Fujiwara M Neuroscience; 2008 Jan; 151(2):320-8. PubMed ID: 18083311 [TBL] [Abstract][Full Text] [Related]
4. Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Schmidt WJ; Bubser M Pharmacol Biochem Behav; 1989 Mar; 32(3):621-3. PubMed ID: 2544900 [TBL] [Abstract][Full Text] [Related]
5. D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats. Verma A; Kulkarni SK Psychopharmacology (Berl); 1992; 109(4):477-83. PubMed ID: 1365866 [TBL] [Abstract][Full Text] [Related]
6. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Hauber W; Andersen R Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):486-90. PubMed ID: 8114947 [TBL] [Abstract][Full Text] [Related]
7. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain. Kaur S; Ozer H; Starr M Eur J Pharmacol; 1997 Aug; 332(2):153-60. PubMed ID: 9286616 [TBL] [Abstract][Full Text] [Related]
8. NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists. Moore NA; Blackman A; Awere S; Leander JD Eur J Pharmacol; 1993 Jun; 237(1):1-7. PubMed ID: 8359205 [TBL] [Abstract][Full Text] [Related]
9. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol. Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647 [TBL] [Abstract][Full Text] [Related]
10. Role of N-methyl-D-aspartate (NMDA) receptors in experimental catalepsy in rats. Mehta AK; Ticku MK Life Sci; 1990; 46(1):37-42. PubMed ID: 2153885 [TBL] [Abstract][Full Text] [Related]
11. Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. Chartoff EH; Ward RP; Dorsa DM J Pharmacol Exp Ther; 1999 Nov; 291(2):531-7. PubMed ID: 10525068 [TBL] [Abstract][Full Text] [Related]
15. Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy. Melo LL; Santos P; Medeiros P; Mello RO; Ferrari EA; Brandão ML; Maisonnette SS; Francisco A; Coimbra NC Brain Res; 2010 Aug; 1349():41-7. PubMed ID: 20558148 [TBL] [Abstract][Full Text] [Related]
16. The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. Kretschmer BD; Zadow B; Volz TL; Volz L; Schmidt WJ J Neural Transm Gen Sect; 1992; 87(1):23-35. PubMed ID: 1346965 [TBL] [Abstract][Full Text] [Related]
17. The NMDA receptor antagonist MK-801 increases morphine catalepsy and lethality. Trujillo KA; Akil H Pharmacol Biochem Behav; 1991 Mar; 38(3):673-5. PubMed ID: 1829839 [TBL] [Abstract][Full Text] [Related]
18. Dopamine D1- and D2-dependent catalepsy in the rat requires functional NMDA receptors in the corpus striatum, nucleus accumbens and substantia nigra pars reticulata. Ozer H; Ekinci AC; Starr MS Brain Res; 1997 Nov; 777(1-2):51-9. PubMed ID: 9449412 [TBL] [Abstract][Full Text] [Related]
19. Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system. Striem S; Bar-Joseph A; Berkovitch Y; Biegon A Eur J Pharmacol; 1997 Nov; 338(3):205-13. PubMed ID: 9424014 [TBL] [Abstract][Full Text] [Related]
20. Drugs which stimulate or facilitate central cholinergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice. Pertwee RG; Ross TM Neuropharmacology; 1991 Jan; 30(1):67-71. PubMed ID: 1646420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]